top of page
Remission of hormone-refractory prostate cancer attributed to Essiac
This case study involves the study of a 64 year old man undergoing treatment for prostrate cancer. The patient was initially treated with androgen deprivation therapy however he soon became resistant to this hormone treatment and his PSA levels elevated. The patient then took essiac tea and the PSA level dropped significantly. It was concluded that Essiac could be proven very useful in cancerous patients but that more clinical studies should be conducted.
Published:
The Canadian Journal of Urology. 2005; 12(5): 2841-2842
Attribution:
Wigdan Al-Sukhni, MD, Ami Grunbaum, Md, Neil Fleshner, MD Division of Urology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Link:
bottom of page